HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $65 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Buy rating for Halozyme Therapeutics, maintaining a price target of $65.
October 04, 2024 | 10:25 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Halozyme Therapeutics, with a maintained price target of $65, indicating continued confidence in the company's stock performance.
The reiteration of a Buy rating and maintenance of a $65 price target by a reputable analyst suggests positive sentiment and potential upside for Halozyme Therapeutics' stock. This could lead to increased investor interest and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100